MoonLake upgraded at Goldman Sachs with the promise of hidradenitis suppurativa property


Detail of the Wall Street sign

Narvik

  • Goldman Sachs upgraded MoonLake Immunotherapeutics (NASDAQ:MLTX) buy from neutral, citing likely positive mid-year Phase 3 results from hidradenitis suppurativa candidate sonelokimab.
  • The investment bank has a price target of $82 (~88% upside from January 16 close).
  • Analyst Richard



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *